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THE GLOBAL BURDEN OF CHRONIC DISEASES
The growing global burden of noncommunicable dis-
eases worldwide has been neglected by policy makers,
major aid donors, and academics. In 2003, there were
56 million deaths globally, 60% of which were due to non-
communicable diseases [1]. These chronic diseases are
the largest cause of the death in the world, led by cardio-
vascular disease (17 million deaths in 2002, mainly from
ischemic heart disease and stroke), followed by cancer
(7 million deaths), chronic lung disease (4 million), and
diabetes mellitus (almost 1 million) [2]. These leading dis-
eases share key risk factors: tobacco use, unhealthy diets,
lack of physical activity, and alcohol abuse [1]. The cur-
rent burden of chronic diseases reflects past exposure to
these risk factors, and the future burden will be largely
determined by current exposures. The global prevalence
of these chronic diseases is increasing, with the major-
ity occurring in developing countries and projected to
increase substantially over the next two decades [3]. Car-
diovascular disease (CVD) is already the leading cause
of mortality in developing countries. Between 1990 and
2020, mortality from ischemic heart disease in developing
countries is expected to increase by 120% for women and
137% for men [4]. Predictions for the next two decades in-
clude a near tripling of ischemic heart disease and stroke
mortality in Latin America, the Middle East, and sub-
Saharan Africa. The global number of individuals with
diabetes in 2000 was estimated to be 171 million (2.8%
of the world’s population), a figure projected to increase
in 2030 to 366 million (6.5%), 298 million of whom will
live in developing countries. Risks for chronic diseases
are also escalating. Smoking prevalence and obesity lev-
els among adolescents in developing countries have risen
considerably over the past decade and portend rapid in-
crease in chronic diseases [5, 6]. Numerous developing
countries and countries in transition have witnessed a
rapid deterioration of their chronic disease risk and mor-
tality profiles [1]. In the world’s most populous country,
China, age-specific death rates from circulatory disease
increased between 200% and 300% in those aged 35
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through 44 years between 1986 and 1999, and by more
than 100% in those aged 45 through 54 years [7].
Chronic diseases have not simply displaced acute in-
fectious ones in developing countries. Rather, such coun-
tries now experience a polarized and protracted double
burden of disease [8]. India, the second most populous
country, has the highest number of diabetics in the world,
and annual coronary deaths are expected to reach 2 mil-
lion by 2010 [9]. The increased burden of chronic diseases
in countries that also have high infectious disease burden
is straining their health services. In all countries, it is also
leading to growing economic costs, with increasing evi-
dence emerging for cardiovascular disease, diabetes, and
obesity [4, 10, 11].
CHRONIC KIDNEY DISEASE AS A RISK
FACTOR FOR CARDIOVASCULAR DISEASE
Chronic kidney diseases (CKD) requiring renal re-
placement therapy (RRT) are rising sharply worldwide,
and the costs for treatments even in developed nations are
becoming staggering. Estimated global maintenance dial-
ysis population is over 1.1 million patients [12]. The size
of this population has been expanding at a rate of 7% per
year. If current trends in end-stage renal disease (ESRD)
prevalence continue, as seems probable, the global ESRD
population will exceed 2 million patients by the year 2010
[13]. The care of this group represents a major societal
commitment: the aggregate cost of treating ESRD during
the coming decade will exceed $1 trillion [13]. The num-
ber of those with a CKD not yet in need of RRT is much
greater, but data on the prevalence of predialysis CKD
are available only as rough estimations at best. One of
the most recent studies is provided by the Third National
Health and Nutrition Evaluation Survey (NHANES III,
1988–1994), which estimated that in the United States ap-
proximately 20 million adults people aged >20 years have
some degree of renal damage [14]. A sizeable proportion
of these people will experience the progression of their
disease to ESRD.
It is increasingly recognized that the burden of CKD
is not limited to its implication on demands for RRT, but
has major impact on overall population health. Indeed,
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patients with reduced kidney function represent a pop-
ulation not only at risk for progression of kidney dis-
ease and development of ESRD, but also at even greater
risk for CVD. In more than 400,000 Medicare patients
with diabetes and CKD, over two years of follow-up, the
risk of death (29%) far exceeded that of development
of ESRD [15]. These findings suggest that CKD patients
who are advancing toward ESRD carry the heaviest bur-
den of CVD, and that this frequently leads to death be-
fore ESRD is reached. The reason why CKD is a risk
factor for cardiovascular outcomes is not entirely clear,
but it seems largely related to the excess prevalence of
traditional cardiovascular risk factors, such as hyperten-
sion, diabetes, and dyslipidemia, associated with the renal
disease. In addition, other factors such as hyperhomo-
cystinemia, abnormalities of mineral metabolism and of
parathyroid function, may become more prevalent and
have pathogenetic relevance as CKD progresses [16, 17].
Even patients with microalbuminuria, but still normal re-
nal function, are at increased risk of cardiovascular mor-
bidity and mortality [18]. Microalbuminuria enhances the
risk for cardiovascular mortality in diabetic patients, as
well as in those with essential hypertension [19–21]. A
large study in the general population also showed that
an increased albumin excretion is associated with en-
hanced mortality, the risk being twice as high compared
to normoalbuminuric subjects [22]. Moreover, investiga-
tors have reported that in a 10-year follow-up of more
that 2000 subjects, the presence of microalbuminuria
more than doubled the predictive effect of the conven-
tional atherosclerotic risk factors for the development of
CVD, such as hypertension and hyperlipidemia [23]. Why
should subjects with microalbuminuria be more prone
to cardiovascular morbidity? A possible explanation is
that the increased urinary albumin excretion is consid-
ered an index of damage of vascular endothelium, which
reflects a generalized endothelial dysfunction that ulti-
mately may contribute to macrovascular disease. Thus,
CKD, through their impact on cardiovascular morbidity,
may directly contribute to the increasing global burden
of death caused by CVD, even in developing countries.
Therefore, these are the patients in whom efforts should
be focused.
THE NOTION OF RENOPROTECTION
Most renal diseases progress to renal failure as a conse-
quence of functional adaptations intervening in the kid-
ney, after the original disease process causes a critical
loss of nephron units. Such changes, extensively stud-
ied in experimental animals, include glomerular hyper-
perfusion and hypertension of the remaining nephrons,
which at the beginning contribute to enhance the filtra-
tion capacity of single nephrons. Over time, however,
kidney hyperfiltration is detrimental [24]. Besides these
compensatory hemodynamic changes, abnormal protein
trafficking through the glomerular capillary barrier might
also contribute to progression of renal disease [25]. Both
in vitro and in vivo experimental evidence have docu-
mented that protein overload of proximal tubular cells
cause increased production of inflammatory and vasoac-
tive mediators, as well as growing factors. They ultimately
promote local recruitment of macrophages and lympho-
cytes in the interstitium, activating fibrogenic processes
and thereby contributing to progressive renal function
loss [26]. The role of proteinuria as a strong, indepen-
dent predictor of ESRD has also been shown in a mass
screening setting [27]. By screening more than 100,000
healthy individuals in 1983 in Okinawa (Japan), and fol-
lowing them for up to 17 years, a positive relationship
between baseline proteinuria and the risk of developing
ESRD was found. Moreover, the predictive value of the
protein excretion rate was independent of the baseline
GFR levels [abstract; Iseki K et al, J Am Soc Nephrol 14:
194A, 2003].
Renoprotection is a strategy that aims to interrupt
or reverse this process. The experimental demonstration
that the blockade of angiotensin II with an angiotensin-
converting enzyme (ACE) inhibitor slowed the progres-
sive loss of renal function in a number of animal models
of renal diseases, including diabetic nephropathy [28, 29],
offered the opportunity to devise a treatment strategy
that was not limited to passively accompanying patients
to their destiny of dialysis, but was aimed at preserving
renal function as long as possible. These and other labo-
ratory studies have generated hypotheses for therapeutic
interventions that have been challenged in several clinical
trials during the past decade [30–32]. Clinical studies have
actually demonstrated for the first time in nephrology that
the once inevitable progressive loss of renal function can
be significantly slowed or even arrested in nondiabetic
and diabetic renal diseases by effectively lowering blood
pressure. Drugs that block the renin-angiotensin system
(RAS) offer additional renoprotection. In the Ramipril
Efficacy In Nephrology (REIN) study, patients with non-
diabetic renal disease and proteinuria received either the
ACE inhibitor ramipril or placebo on top of the con-
ventional antihypertensives. Ramipril lowered by 50%
the rate of decline of the GFR and reduced the need
for dialysis [32]. The results of other studies were sum-
marized in a meta-analysis of 11 clinical trials done in
patients with proteinuric nephropathies. They showed
that ACE inhibitors limit GFR decline and disease pro-
gression considerably better than other antihypertensives
[33]. The renoprotective effects of angiotensin type 1 re-
ceptor blockade (ARB) have been also demonstrated in
three large clinical trials in patients with type 2 diabetic
nephropathy [34–36]. One study evaluated the renopro-
tective effect of ARB irbesartan in hypertensive patients
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with incipient nephropathy [34]. The end point of the
study was the time of onset of overt albuminuria. In two
years’ follow-up, only 5.2% of patients receiving 300 mg
of irbesartan reached the end point compared with 14.9%
of patients on placebo. The groups had similar blood pres-
sure control, a finding that suggests that ARBs are reno-
protective independently of their antihypertensive effect.
The role of ARB in overt diabetic nephropathy was ex-
plored in two other trials published in 2001 [35, 36]. In
both studies, treatment with ARB resulted in a signifi-
cant reduction of proteinuria, the incidence of doubling
serum creatinine, and the risk of end-stage renal disease.
Although we have limited our review to only a few clini-
cal studies, several other trials have been published, some
of them small in size, with little statistical power, and with
short follow-up. However, they all point in one direction:
blockade of renin-angiotensin system is beneficial in most
proteinuric chronic nephropathies.
The evidence from clinical trials suggests that the cur-
rent practice can, at best, postpone end-stage renal dis-
ease for few years, and not avoid dialysis for most patients
during their lifetime. Nevertheless, significant reduction
of the incidence of end-stage renal disease is likely to be
achieved in the next future for chronic nephropathies,
provided that we can improve the degree of renoprotec-
tion. This goal may be attainable with a more complex
strategy than with a single pharmacologic intervention
[37]. It has also emerged that the disease remission in pa-
tients with chronic nephropathies requires a multitask
approach, which should include—in addition to blood
pressure and proteinuria control—treatment of dyslipi-
demia, tight glycemic control in diabetics, control of
other metabolic abnormalities (e.g., metabolic acidosis,
calcium homeostasis), and lifestyle modification (exer-
cise, banning of smoking, body weight reduction) [38,
39]. The efficacy of the multifactorial strategy is sup-
ported by a target-driven long-term intensified interven-
tion aimed at multiple risk factors in 80 patients with
type 2 diabetes and microalbuminuria, which reduced
the risk of nephropathy, cardiovascular, and microvas-
cular events by about 50% [40]. In a series of ours, 26
patients whose proteinuria had been at least 3 g for more
than six months despite ACEI therapy were given a stan-
dardized multidrug treatment including diuretics, ACEi,
ARB, statins, and non-dihydropyridine calcium channel
blockers. Nineteen (73%) of these patients achieved full
remission of proteinuria, and their renal function stabi-
lized over 24 months. Whether renal damage can also be
reduced in parallel with clinical remission is still a matter
of investigation. In support is the evidence by repeated
biopsy for a trend of renal damage to regress, leading to
less mesangial expansion, more open capillaries, and less
interstitial fibrosis [41]. At least 10 years were needed to
reverse the lesions, which is entirely consistent with the
concept that the timing of institution of therapy, beside
the drug doses and combinations, is critical in the human
setting, exactly like in the experimental animal [42].
Regression of lesions may have significant impact on
progressive renal disease and its sequelae. One might
wonder why we should pursue the goal of improving re-
nal structure and function, if we can already successfully
stabilize the disease perhaps for a lifetime. First and most
obviously, improving renal function may have a major
effect in reducing the number of patients with chronic re-
nal disease that progresses to ESRD. Any improvement
of renal structure and function should also translate into
less risk of ESRD for those who have less compromised
renal function. This would apply both to young patients
and to the elderly, who may incur more critical renal and
cardiovascular risks. The economic impact of even a par-
tial improvement would be enormous, as documented by
findings that a 30% reduction in the rate of GFR decline
would translate in more than $60 billion saved for pro-
viding renal replacement therapy to patients progressing
to ESRD in the United States by the year 2010 [43]. Fi-
nally, in certain settings, such as membranous nephropa-
thy, focal and segmental sclerotic lesions predict worse
prognosis. What would happen if we could revert them?
Understanding the mechanisms by which a given lesion
may regress, and its relationship to function, will be cru-
cial to dissect the relevant renal cell biology and thera-
peutic targets. Once again, investigation in experimental
models will prove indispensable to the new task, and will
clarify whether renal damage can be reverted to such a
point that renal function may be fully prevented from
worsening, and possibly improve.
Although findings demonstrate that the treatment of
ESRD is a success of public health—since before its in-
ception in the late sixties, the disease was universally
fatal—they also pose a major challenge to the health care
systems. Provision of adequate facilities, equipment, and
manpower to assist to the growing number of patients
with ESRD will pose a substantial burden on health care
resources. The cost and complexity of RRT puts it out
of reach of developing countries. In the future, even de-
veloped countries will be overwhelmed by the number
of people with ESRD to treat, and may face financial
constraints that could limit the availability of treatment.
Therefore, efforts to implement preventive interventions
are worthy either in poor or rich countries.
EARLY DETECTION AND INTERVENTION
PROGRAMS FOR CHRONIC KIDNEY DISEASES
The objective of early diagnosis is the early detection
of asymptomatic disease when intervention has a rea-
sonable potential to have a positive impact on outcome.
Chronic care has tended to screen high-risk individuals
with a high probability of contracting chronic diseases.
Yet for chronic diseases, most risk factors are widely
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distributed in the population, with all individuals at risk
but differing in the extent of their risk [44]. Prevention
and treatment, therefore, requires a sustained, multisec-
torial commitment well beyond the traditional health sec-
tor. In recent years, a number of screening strategies have
been implemented for the detection of CKD. Some have
focused on the entire population, while others targeted
a specific group within the population. A general pop-
ulation screening, the NHANES III, was carried out in
the United States from 1988 to 1994. It involved 15,626
participants, and determined the prevalence of the var-
ious stages of CKD in the U.S. adult population using
spot urine albumin and calibrated serum creatinine lev-
els [45]. It reported that the overall prevalence of CKD
among the population was 11% (19 million U.S. adults). In
Europe, the Prevention of End-Stage Renal and Vascular
End-points (PREVEND) study undertaken in the city of
Groningen (The Netherlands) evaluated almost 40,000
individuals in a cross-sectional cohort study [22]. It was
found that around 7% of those screened had albuminuria.
Individuals with the highest level of albuminuria had,
over a 3-year follow-up period, the highest incidence of
cardiovascular death [22]. The National Kidney Founda-
tion of Singapore has set up a comprehensive program for
CKD prevention, initiated in 2000, and is currently eval-
uating about 450,000 subjects [46]. The program detected
significant urinary abnormalities (ranging from 5%–8%
proteinuria and/or hematuria) among the general popula-
tion and high-risk individuals with family history of renal
insufficiency [46]. In the Okinawa screening program, in
more than 100,000 individuals, obesity, dyslipidemia, and
smoking were identified as significant risk factors for the
subsequent development of albuminuria, in turn a major
risk factor for the development of ESRD [47].
It has been shown in limited, although extremely im-
portant, experiences that programs aimed to reduce the
burden of CKD are feasible also in poor countries and
among underprivileged communities. The Kidney Help
Trust of Chennai, India [48] has embarked in a screening
program in an area of 25,000 people. Trained social and
health workers have recorded blood pressure, checked
for abnormal glucose levels, and for presence of albumin
in the urine. All those who were positive for high blood
pressure, diabetes, or both were further studied and then
treated with inexpensive antihypertensive and antidia-
betic drugs. The cost of a one-year program has been
300,000 Indian rupees (i.e., $ 6500 per year); per capita
costs were $0.30, well within the limit of Indian govern-
ment per capita health expenditure of $8. An excellent
blood pressure control was achieved among hypertensive
patients, while blood glucose control in diabetics was con-
sidered good. Another experience of mass screening for
kidney disease has been conducted, at very low costs, in
Bolivia under the auspices of the ISN-COMGAN [49].
More than 14,000 people were screened for urinary ab-
normalities in three regions of Bolivia (urban, mountain,
and forest areas) by social workers. A portion of the pa-
tients who were found positive at first screening was then
enrolled in a follow-up program. Among Australian Abo-
rigines, a very successful targeted program of detection
and treatment of renal and cardiovascular diseases was
conducted from 1995 to 2000 [50]. After an average of
3.4 years of follow-up with ACE inhibitor treatment, the
incidence of ESRD was reduced by 63%, and the nonre-
nal death of 50%. From this study it has been estimated
that at two years, this program may have allowed a saving
of $800,000 Aus to $4.1 million in costs of dialysis avoided
or delayed. The COMGAN Research Committee of the
International Society of Nephrology is now developing
a global early detection and intervention program for
emerging countries that would be implemented accord-
ing to the peculiar needs and organization facilities of the
given country. It is expected that such a kind of population
screening can increase health awareness, particularly in
countries with less sophisticated health systems, and help
detect a significant proportion of underdiagnosed individ-
uals with chronic renal and/or cardiovascular diseases.
CHALLENGES WITH RESPECT TO HUMAN
RESOURCES
In most developing countries, lack of manpower to
address chronic diseases has been a major impediment
to chronic disease control. Other impediments are the
failure to provide key decision makers with up-to-date
evidence on the burden of chronic diseases; a lack of
understanding of the economic factors that influence
chronic disease risks; and the current orientation of
health systems toward acute care. Screening and inter-
vention programs require considerable resources both in
terms of manpower and funds. While there is no doubt
that the money is indispensable for providing drugs, and
everything else is needed to prevent and treat progres-
sive chronic kidney diseases, the manpower to imple-
ment epidemiologic and therapeutic programs are also
indispensable. To this purpose, an important point is the
need of a commitment to create an in-country human ca-
pacity that can determine for itself the local problems,
and not to translate the Western needs into problems of
a given emerging country. The training of doctors and
nurses from emerging countries in Western centers can
be supported by special grants. However, approaches that
focus on the training of individuals that do not take into
account the work environment can enjoy only limited
success. Far more important is the need to strengthen
the health care workforce in communities and districts to
address the health challenges, and to use the resources
and interventions for effective care and management of
systems. This is why the institutions in developed coun-
tries have an ethical obligation to facilitate the return of
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health professionals to developing countries. This applies
particularly to nurses who should be encouraged to offer
their precious skills to their people in their own countries;
the present trend to attract nurses from poor countries to
the rich ones, where there is a chronic lack of these pro-
fessionals, should be reversed, providing the profession-
als with adequate conditions and pay. Besides training of
personnel in Western countries, the prevention programs
should plan regular on-site education by experts from the
developed world. Nevertheless, such exchanges may re-
veal mutually instructive. The great value in developing
academic partnerships between developed and develop-
ing countries is that they function on a personal basis to
the mutual advantage of both parties, and, above all, are
sustainable.
A FUND FOR COMBATING CHRONIC KIDNEY
DISEASES IN EMERGING COUNTRIES
Chronic disease control is not necessarily expensive.
Several clinical and public health interventions have the
potential to reduce the burden of disease from cardio-
vascular disease, diabetes, and hypertension significantly
and at relatively low cost [1]. A number of strategies have
been devised to increase the access to essential medicine
where they are most needed, from discounted prices for
medicine, softening of patent protection, and drug do-
nation [51]. But the implementation of the prevention
program requires not only medicinal products, but also
equipment, creation of research institution, and educa-
tion and training of health professionals. Much current
thinking about how to direct the resources of richer coun-
tries for the benefit of the health of the developing world
revolves around government aid, tax incentives to en-
courage the pharmaceutical industry to tackle some of its
problems, the mobilization of earmarked funds by non-
government organizations, and hopes for further large
donations from philanthropic bodies. Concern exists
about the efficiency, bureaucracy, and, above all, sustain-
ability of many of these international sources of funding.
An attractive novel model to overcome these shortcom-
ings is—by analogy with the Global Fund to Fight AIDS,
Tuberculosis and Malaria—to create a ‘Global Fund For
Kidney Diseases.’ This should be coordinated by the
ISN-COMGAN, and supported by resources made avail-
able yearly from different institutions/organizations. An
important contribution should be provided by national
nephrology societies of Western countries. Also, phar-
maceutical companies may be asked to contribute in
supporting with donations to a global fund for kidney
disease. The sale of antihypertensive drugs, and especially
ACE inhibitors, has been very successful, and these drugs
granted big returns to their manufactures: a donation of
a small proportion of the revenues may be taken in con-
sideration. The contribution by the industry to the fund
for the advancement of the global health, even with small
part of the profit, is a moral obligation. Nevertheless, the
implementation of such a program cannot be realized
without the involvement at the local level of national sci-
entific societies and health authorities.
CONCLUSION
Medicine is developing evidence for noncommunica-
ble chronic disease, including cardiovascular and kidney
diseases, but has no equity plan. A more concerted, strate-
gic, and multisectorial approach, underpinned by solid
research, is essential to help reverse the negative trends
in incidence of these chronic diseases, not just for a few
beneficiaries but on a global health equity program.
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